65.51 USD
-4.47 (-6.39%)
Last: Jan 30, 2026, 08:00 PM
Overall APGE gets a fundamental rating of 3 out of 10. We evaluated APGE against 525 industry peers in the Biotechnology industry. While APGE has a great health rating, there are worries on its profitability. APGE does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- APGE had negative earnings in the past year.
- In the past year APGE has reported a negative cash flow from operations.
1.2 Ratios
- Looking at the Return On Assets, with a value of -40.51%, APGE is in line with its industry, outperforming 58.67% of the companies in the same industry.
- APGE has a better Return On Equity (-43.26%) than 69.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -40.51% | ||
| ROE | -43.26% | ||
| ROIC | N/A |
ROA(3y)-23.75%
ROA(5y)N/A
ROE(3y)-25.17%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for APGE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The number of shares outstanding for APGE has been increased compared to 1 year ago.
- APGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- APGE has an Altman-Z score of 70.41. This indicates that APGE is financially healthy and has little risk of bankruptcy at the moment.
- APGE has a better Altman-Z score (70.41) than 97.52% of its industry peers.
- There is no outstanding debt for APGE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 70.41 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 15.86 indicates that APGE has no problem at all paying its short term obligations.
- APGE has a better Current ratio (15.86) than 92.76% of its industry peers.
- A Quick Ratio of 15.86 indicates that APGE has no problem at all paying its short term obligations.
- The Quick ratio of APGE (15.86) is better than 92.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 15.86 | ||
| Quick Ratio | 15.86 |
3. Growth
3.1 Past
- APGE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -81.22%.
EPS 1Y (TTM)-81.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- APGE is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -7.92% yearly.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-30.72%
EPS Next 2Y-24.03%
EPS Next 3Y-23.06%
EPS Next 5Y-7.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for APGE. In the last year negative earnings were reported.
- Also next year APGE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as APGE's earnings are expected to decrease with -23.06% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.03%
EPS Next 3Y-23.06%
5. Dividend
5.1 Amount
- APGE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
APOGEE THERAPEUTICS INC / APGE FAQ
What is the ChartMill fundamental rating of APOGEE THERAPEUTICS INC (APGE) stock?
ChartMill assigns a fundamental rating of 3 / 10 to APGE.
Can you provide the valuation status for APOGEE THERAPEUTICS INC?
ChartMill assigns a valuation rating of 0 / 10 to APOGEE THERAPEUTICS INC (APGE). This can be considered as Overvalued.
Can you provide the profitability details for APOGEE THERAPEUTICS INC?
APOGEE THERAPEUTICS INC (APGE) has a profitability rating of 1 / 10.
How financially healthy is APOGEE THERAPEUTICS INC?
The financial health rating of APOGEE THERAPEUTICS INC (APGE) is 8 / 10.